Search
State of Possible: Beam Therapeutics' CEO John Evans discusses the company's recent alpha-1 antitrypsin deficiency data, what's ahead for sickle cell disease, and the current environment for biotech
He describes the nine patient dose ascending data in AAT deficiency that was historic for being the industry's first in-vivo proof of...
Mar 26
ASH 2024: Beam's CEO John Evans on the company's based editing sickle cell data, and preclinical data on a next generation product meant to broaden the potential patient population
He describes clinical data presented at ASH for BEAM-101 and how he believes it stacks up against competition that is on the market....
Dec 8, 2024
Behind-the-scenes of base editing at Beam Therapeutics
CEO John Evans gives an update on Beam's pipeline and then we take a lab tour to see the science in action with President Pino Ciaramella.
Oct 6, 2023
Beam's Therapeutics' John Evans talks base editing at #JPM23
John Evans talks about base editing as a tool for genetic diseases and cell therapy engineering.
Jan 9, 2023
.png){kind=logo}
